Tejo Niharika Musunuru, MD

Hematologist and Medical Oncologist at @MDAndersonNews @utmbhealth #EndCancer

[Tejo Niharika Musunuru, MD @TejoMusunuru]

Well deserved recognition for a true legend @DrHKantarjian So glad to be a part of his #Leukemia team. He is phenomenal.. a true inspiration for the junior faculty.

[UT MD Anderson @UTMDAnderson]

We are proud to celebrate our Dr. Hagop Kantarjian receiving the prestigious David A. Karnofsky Memorial Award from @ASCO for his contributions to leukemia care and research. @DrHKantarjian #ASCO23 #EndCancer [1/3]

[Hagop Kantarjian,MD @DrHKantarjian]

Patients with #CML and bariatric surgery have suboptimal responses to oral TKIs therapy.
@FadiHaddad_MD and @GhayasIssa of @MDAndersonNews #Leukemia
https://t.co/hogGryHWQd @JournalCancer
#leusm #endcancer

[Tejo Niharika Musunuru, MD @TejoMusunuru]

@esinghimd @MDAndersonNews That is one of my favorite mugs! Makes you proud to be a doctor.

[Hagop Kantarjian,MD @DrHKantarjian]

Led by our own Dr. Verstovsek of @MDAndersonNews #Leukemia, important Ph3 study MOMENTUM: Momelotinib vs danazol resulted in clinically significant improvements in MF-associated anemia+sxs+spleen response+favorable safety.
https://t.co/j1dR6VRi9E @TheLancet
#MPNSM

[Tejo Niharika Musunuru, MD @TejoMusunuru]

@ssrajamouli might like how his magnus opus is being used in medical field. Aza+Ben synergism, multiple courses needed, some soldiers hide and come back #loveIt #leusm

[Amer Zeidan عامر زيدان @Dr_AmerZeidan]

Venetoclax and azacitidine synergistically going after #AMLsm #leukemia blasts

[Tejo Niharika Musunuru, MD @TejoMusunuru]

I hope #2023NewYear brings new hopes, health and happiness to everyone. Overjoyed to enter another year to do my part in #Makingcancerhistory and bringing smiles to a lot of people @MDAndersonNews @utmbhealth

[Robert Brodsky @DocsDock200]

#hematology predictions for 2023: 1) single-board #classicalhematology will become fastest growing subspecialty in internal medicine. Thanks #HFFTP; 2) #bmt: Indications for BMT will decline for malignant disease...

[Nico Gagelmann @NicoGagelmann]

I believe it is important in medicine and in life to understand the history to evaluate the present and to shape the future.

Therefore, a short ����on the early history of myelofibrosis.

#MedTwitter #MedStudentTwitter #mpnsm

[ASH @ASH_hematology]

ASH has adopted the term "classical hematology," in place of what was formerly referred to as "benign" or "nonmalignant." Discoveries within #classicalheme have significantly advanced the field & continue to better the lives of those living with non-cancerous blood disorders.
1/2

[Tejo Niharika Musunuru, MD @TejoMusunuru]

@calliecoombsmd Interesting findings. Thank you!

[MDS Hub @MDS_Hub]

CONGRESS | #ASH22
Naval Daver @Daver_Leukemia, @MDAndersonNews presented phase Ib/II trial of pivekimab sunirine (PVEK)+Aza+Ven triplet in R/R AML. In 91 patients, ORR = 45% and composite CR = 25% (duration 7.7 months), with a manageable safety profile. #leusm

[Tejo Niharika Musunuru, MD @TejoMusunuru]

@szusmani So sorry for your loss. My deepest condolences.

[Tejo Niharika Musunuru, MD @TejoMusunuru]

#NewProfilePic

[Tejo Niharika Musunuru, MD @TejoMusunuru]

@drkomanduri @ASH_hematology The science behind the bourbon st energy….and the art of #NOLA food…

[Tejo Niharika Musunuru, MD @TejoMusunuru]

Brain’s filled with #ASH2022 info… now’s the time to fill the tummy.. What are the never miss eatery places in NOLA? #firsttime #Goodfood

[Tejo Niharika Musunuru, MD @TejoMusunuru]

@NazliDizman @MDAndersonNews @montypal @DrChoueiri @JenWargoMD @OncHahn @PavlosMsaouel @PGrivasMDPhD @neerajaiims @NarjustFlorezMD @MarkDSiegel1 @YaleIMed @DelaCruzYaleMed Congratulations!

[Tejo Niharika Musunuru, MD @TejoMusunuru]

@1pooj Congratulations on the match!! #hemonc @utmbhealth
Excited to see your achievements over the next 3 years. All the best!

[Tejo Niharika Musunuru, MD @TejoMusunuru]

@s_arora96 @MDAndersonNews @uabimres @ONealCancerUAB Congratulations and all the best!

[Hagop Kantarjian,MD @DrHKantarjian]

Chemo-free combination of ponatinib + blinatumomab is potentially curative in Ph+ ALL w/o need for intensive chemo or allo-SCT. This is new standard of care in Ph+ ALL.
Jabbour, Short, Kantarjian of @MDAndersonNews #Leukemia https://t.co/gKPyzpRiiI via @TheLancetHaem
#leusm

[Tejo Niharika Musunuru, MD @TejoMusunuru]

Happy #Diwali2022. A festival without borders as we celebrate the victory of good over evil, light over dark and resilience over suffering. May the Festival of Lights remove any darkness in our lives. #endcancer #celebration